Guest guest Posted October 21, 2003 Report Share Posted October 21, 2003 Mon, 20 Oct 2003 09:37:23 -0500 HSI - Jenny Thompson Crashing the Market Crashing the Market Health Sciences Institute e-Alert October 20, 2003 ************************************************************** Dear Reader, Most of us can't help it. When we see a car wreck on the highway, we slow down to catch a glimpse. That's the feeling I had while reading about two drug giants colliding in the marketplace. And it's shaping up to be quite a car wreck. So we're going to slow down a bit to take a look. In last week's " Cresting the Wave " (10/15/03) I told you about the launch of a new cholesterol-lowering statin drug called Crestor, manufactured by AstraZeneca (AZ), the fifth largest drug company in the world. AZ reps have made no secret of their hopes that Crestor will effectively rival Pfizer's Lipitor, the long-time statin king with annual sales of about $8 billion. Excuse me for saying it, but that takes some brass. Brass bumpers, that is. Because when you gun your car through that kind of heavy traffic, you're bound to get banged around by the FDA approval process and insurance companies, while charting a high-speed collision course with the big Hummer: Lipitor. Quick - someone call 911! ----------------------------- How fast was I going, officer? ----------------------------- AstraZeneca's pitch for Crestor is that it's less expensive and more effective than Lipitor, with similar side effects. And the new drug is already selling like hotcakes in the U.K., Canada, and several other countries where it's been available since last February. Meanwhile, here in the U.S., the FDA pulled Crestor over for doing 80 in a 40. In the original clinical trials presented to the FDA, some of the subjects who took 80 mg developed kidney damage. (Not really all that shocking given that, as a class of drugs, statins have always been associated with kidney toxicity.) So the folks at the FDA said, " Try again, " and AZ resubmitted Crestor at doses of 40 mg or less. The FDA gave the green light, and Crestor was introduced in the U.S in September. ----------------------------- Stuck in traffic ----------------------------- Within just a couple of weeks of Crestor's U.S. launch, AstraZeneca announced that the new drug had already captured more than 2 percent of the new prescriptions written for statin drugs in the U.S. These impressive stats were released at a high-profile meeting with investors at AZ's U.S. headquarters in Fairfax, VA. But the party was spoiled when, that very same day, Wellpoint (the second largest private health insurer in the U.S.) announced that prescriptions for Crestor would not be covered because of concerns over the safety of the drug. This was a blow. It meant that more than 13 million Americans in the Wellpoint system would have to pay for Crestor out of pocket. But perhaps even worse than that, when reps for Wellpoint made the announcement, they used the " B " word: Baycol. Baycol was A.G. Bayer's entry into the statin market a few years ago, and talk about car wrecks! In the e-Alert " Pot, Meet Kettle " (3/5/03) I told you how Baycol had been yanked from the market in 2001 because of adverse reactions, including acute kidney failure and more than 30 deaths. Bayer was sued by thousands of patients, and spent well over a $1 million settling many of the cases out of court. So when Dr. Robert Seidman, Wellpoint's chief pharmacy officer, told reporters that the insurance company was being cautious because, " We've already been Baycolled, " the seed of doubt was planted by making the association between Bayer's dangerous product and the kidney problems attributed to Crestor in those early 80 mg trials that the FDA rejected. So was Wellpoint simply protecting clients by denying the Crestor coverage? Tom McKillop, AZ's chief executive, reportedly told a writer for TheStreet.com, " I don't believe for a moment that it's about side effects. " ----------------------------- Crazy like a fox ----------------------------- Less than a week after Wellpoint ruined AZ's day, Reuters reported that a new UK study had revealed that in a group of 14,000 heart disease patients, statins failed to lower cholesterol to recommended levels in about half the subjects. The headline read: " Statin Drugs Fail Half UK Heart Patients- Study. " Now you might think that on the heels of this news AZ executives would have started pulling out their hair again, but not so. Because the statin drugs this study focused on were the older statins, such as atorvastatin (brand name: Lipitor) and simvastatin (brand name: Zocor). The newer type of statin drug known as rosuvastatin (brand name: Crestor) wasn't included in the study. So this was a lucky break for AZ, right? Well, it was perhaps more than just a break. Because the research was sponsored by AstraZeneca. I'm not saying anyone falsified the results. They didn't need to. Previous studies have already shown that statin drugs significantly lower cholesterol in less than half of those who take them. So the " failed " effectiveness was virtually a foregone conclusion. ----------------------------- I brake for drug giants ----------------------------- See where this is going? With large shares of a $20-billion- per-year statin market at stake, the players in this market aren't going to leave anything to chance. According to one report, AstraZeneca may be planning to invest as much as $1 billion to promote Crestor this year. That means two things: 1) We'll be seeing even more commercials warning us that we must save our lives by taking statins to lower our cholesterol, and 2) These Goliaths - Crestor and Lipitor - are on a collision course, with Zocor right there in it with them as well. I'll keep you posted as more details are reported. Until then... buckle up! It's going to be a bumpy ride. ************************************************************** To start receiving your own copy of the HSI e-Alert, visit: http://www.hsibaltimore.com/ealert/freecopy.html Or forward this e-mail to a friend so they can sign-up to receive their own copy of the HSI e-Alert. ************************************************************** ... and another thing And now, back to reality... While researching today's e-Alert I came across an item I told you about last year. The World Heart Federation (WHF) issued a statement warning that a lack of physical activity doubles your chances of developing heart disease while increasing the risk of high blood pressure and type 2 diabetes. The WHF estimates that as much as 85% of the world's population fails to get even moderate exercise. So, if you're part of that scant 15%, you're doing the single most important thing you can do to increase your exercise capacity, enhance your immune system, and make your heart a little healthier every day. And if you can't put aside a half hour every day for light exercise, three 10-minute exercise sessions per day are just as good, according to research from the UK. The study concluded that middle-aged men and women who take three 10- minute brisk walks each day showed just as much improvement in their cardiovascular health as subjects who walked for 30 minutes at a stretch each day. They just keep making it harder for us to find excuses, don't they? To Your Good Health, Jenny Thompson Health Sciences Institute ************************************************************** Sources: " The New Statin " Nicholas Regush, Red Flags Weekly, 10/6/03, redflagsweekly.com " AstraZeneca's Crestor " Jeff Hwang, The Motley Fool, 10/2/03, fool.com " US Blow to AstraZeneca " Nils Pratley, The Guardian, 10/4/03, guardian.co.uk " AstraZeneca: U.S. Crestor Sales Encouraging " Ben Hirschler, Reuters, 10/2/03, reuters.com " Insurer Will Not Cover Crestor " Fred Biddle, The News Journal, 10/2/03, delawareonline.com " Statin Drugs Fail Half UK Heart Patients - Study " Reuters, 10/5/03, reuters.com " Lack of Exercise 'Damages Heart' " BBC News, 9/23/02 " Accumulating Brisk Walking for Fitness, Cardiovascular Risk, and Psychological Health " Medicine & Science in Sports & Exercise, 2002, Sep;34(9):1468-74 Copyright ©1997-2003 by www.hsibaltimore.com, L.L.C. The e-Alert may not be posted on commercial sites without written permission. ************************************************************** Before you hit reply to send us a question or request, please visit here http://www.hsibaltimore.com/ealert/questions.html ************************************************************** ************************************************************* If you'd like to participate in the HSI Forum, search past e-Alerts and products or you're an HSI member and would like to search past articles, visit http://www.hsibaltimore.com ************************************************************** To learn more about HSI, call (203) 699-4416 or visit http://www.agora-inc.com/reports/HSI/WHSID618/home.cfm. ************************************************************** If you want to end your HSI e-Alert subscription or you need to change your e-mail address, please follow the instructions below. Your changes will be effective immediately. However, if you do not follow the instructions below and simply hit reply instead, we may not receive your request and cannot assure you that it will be completed. ******* To manage your e-mail subscription, use our web interface at: http://www.agoramail.net/Home.cfm?List=hsiweb To cancel or for any other subscription issues, write us at: Order Processing Center Attn: Customer Service P.O. Box 925 Frederick, MD 21705 NEW WEB MESSAGE BOARDS - JOIN HERE. Alternative Medicine Message Boards.Info http://alternative-medicine-message-boards.info The New with improved product search Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.